AJ8.F Agenus Inc.
- Market cap
- EUR 290M
- P/E
- 32.0x
- P/B
- 181.30x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is AJ8.F undervalued?
Graham numberThe Graham number of Agenus Inc. cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Agenus Inc. fundamental analysis
No fundamental analysis for Agenus Inc. yet.
Agenus Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Agenus Inc.
Agenus Inc., a clinical-stage biotechnology company, discovers and develops immunotherapies for cancer and infectious diseases in the United States and internationally. It offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, a programmed death receptor-1 (PD-1) b…
Full company profileAgenus Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Agenus Inc. annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 296M | 98.0M | 156M | 103M | 114M | 133M |
| Gross Profit | 114M | -99.2M | -81.4M | -52.6M | 33.8M | 82.0M |
| Operating Income | 37.2M | -180M | -160M | -124M | -20.6M | 50.3M |
| EBITDA | - | -162M | -146M | -101M | 62.2M | 117M |
| Net Income | -23.9M | -220M | -246M | -227M | 115K | 55.2M |
| EPS | -1.86 | -14 | -12 | -9.61 | 0.00 | 1.22 |
| Balance Sheet | ||||||
| Total Assets | 466M | 414M | 314M | 226M | 227M | 246M |
| Total Liabilities | 418M | 468M | 462M | 533M | 505M | 358M |
| Shareholders' Equity | 34.4M | -61.3M | -160M | -326M | -271M | -105M |
| Cash & Short-term Investments | 292M | 179M | 76.1M | 40.4M | 3.00M | 66.9M |
| Cash Flow | ||||||
| Operating Cash Flow | 10.1M | -175M | -224M | -158M | -77.2M | -116M |
| Capital Expenditure | 33.8M | 53.1M | 9.95M | 576K | 6.00K | 0.00 |
| Free Cash Flow | -23.7M | -228M | -234M | -159M | -77.2M | -116M |
| Ratios | ||||||
| ROE | -69.5% | - | - | - | - | - |
| ROA | -5.1% | -53.2% | -78.3% | -100.4% | 0.1% | 22.5% |
| Net Profit Margin | -8.1% | -224.5% | -157.2% | -219.6% | 0.1% | 41.5% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Agenus Inc. dividends
Agenus Inc. has not paid dividends in the last 5 fiscal years.
Last stock split: 1:20 on Apr 12, 2024.
Who owns Agenus Inc.
- Insiders 6.24%
- Institutions 44.11%
- Public & others 49.66%
- Shares outstanding 45.2M
- Free float 40.5M
Agenus Inc. company profile
- Company name
- Agenus Inc.
- Ticker
- AJ8.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 81
- Fiscal year end
- December
- Address
- 3 Forbes Road, Lexington, MA, United States, 02421-7305
- Phone
- 781 674 4400
- Website
- agenusbio.com
About Agenus Inc.
Agenus Inc., a clinical-stage biotechnology company, discovers and develops immunotherapies for cancer and infectious diseases in the United States and internationally. It offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, a programmed death receptor-1 (PD-1) blocking antibody; AGEN1181, a human Fc-enhanced cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody that is in Phase 2 trials in metastatic colorectal cancer (mCRC), pancreatic cancer, and melanoma; AGEN2373, a CD137 monospecific antibody that is in Phase 1b clinical trial; AGEN1423, a CD73/TGFß TRAP antibody; AGEN1571, an ILT2 monospecific antibody that is in clinical development; and BMS-986442, a TIGIT bispecific antibodies. In addition, it develops INCAGN1876, a GITR agonist; INCAGN2390, a TIM-3 monoclonal antibodies; INCAGN2385, a LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4 that is in Phase 2 clinical trial; and AGEN1884. The company operates under the Agenus, MiNK, Prophage, Retrocyte Display, and STIMULON trademarks. It has collaborations with Bristol-Myers Squibb Company, Betta Pharmaceuticals Co., Ltd., UroGen Pharma Ltd., Gilead Sciences, Inc., Incyte Corporation, and Merck Sharp & Dohme. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.
Agenus Inc. management
10- Dr. Garo H. Armen Ph.D.Founder, Interim CFO, Principal Financial Officer, CEO & Executive Chairman · born 1953
- Dr. Steven J. O'Day M.D., Ph.D.Chief Medical Officer · born 1961
- Dr. Jennifer S. Buell Ph.D.Director and President & CEO of MiNK Therapeutics · born 1975
- Craig WinterChief Information Officer
- Mr. Zack ArmenVice President of Investor Relations & Corporate Development
- Ms. Stefanie Perna-NacarChief Communications & Government Relations Officer
- Ms. Tracy Mazza ClementeChief People Officer
- Dr. Todd Jude Yancey M.D.Member of Advisory Board & Chief Strategic Advisor
- Dr. Robin G. Taylor M.B.A., Ph.D.Chief Commercial Officer
- Dr. Kamel Djazouli M.D.Head of Medical Affairs